Study Title: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Dincman, Toros, at dincmant@musc.edu.Study Coordinator, Concepcion, Holly, at concepch@musc.edu.Ralph H. Johnson VAMCStudy Coordinator, Jeter, Kathy, at katherine.jeter2@va.gov.Trial opened at the following institutions: Ralph H. Johnson VAMC, Medical University of South Carolina